Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Anatomical Resection in Colorectal Liver Metastases Patients
Completed
- Conditions
- The Characteristics of CRLM Patients Who Would Benefit More From Anatomical Resection
- Interventions
- Procedure: Anatomical Resection
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 729
- Registration Number
- NCT05673564
Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 53
- Registration Number
- NCT05673824
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
Phase 2
Recruiting
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: Camrelizumab+cetuximab+chemotherapy
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT05673577
- Locations
- 🇨🇳
Fudan University, Shanghai, China
a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy Without Biopsy
Not yet recruiting
- Conditions
- Prostate BiopsyProstatic NeoplasmsProstatectomy
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 71
- Registration Number
- NCT05670691
A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
Phase 2
Recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT05670925
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
Phase 2
Recruiting
- Conditions
- Biliary Tract Carcinoma
- Interventions
- Combination Product: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 93
- Registration Number
- NCT05668884
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Feasibility in Identification of Breast Cancer Candidates for Elimination of Axillary Surgery
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Diagnostic Test: Ultrasound-guided core needle biopsy in breast
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 191
- Registration Number
- NCT05663021
- Locations
- 🇨🇳
Zhi-Min Shao, Shanghai, Shanghai, China
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
Phase 4
Not yet recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Drug: Targeted drugs combined with anti-PD-1/PD-L1 antibodiesDrug: TACE (transarterial chemoembolization) combined with targeted/immunotherapyDrug: Lenvatinib monotherapyDrug: Huaier granules combined with any of the above Cohorts for treatment
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 750
- Registration Number
- NCT05660213
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
Not yet recruiting
- Conditions
- Locally Advanced Rectal CarcinomaMSI-High
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 38
- Registration Number
- NCT05645094
Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy
Phase 1
Not yet recruiting
- Conditions
- Metastatic Liver Cancer
- Interventions
- Drug: HAIC、Bevacizumab、Camrelizumab
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT05643417
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath